8-K: XOMA Royalty Corp Expands Portfolio with $15 Million Twist Bioscience Deal

XOMA Royalty Corporation has acquired a 50% stake in future milestones and royalties from over 60 early-stage programs of Twist Bioscience for $15 million.

Summary

• XOMA Royalty Corporation has purchased a 50% economic interest in future milestone and royalty payments from Twist Bioscience's 60+ early-stage programs across 30 partners.
• The deal involved a $15 million upfront cash payment from XOMA to Twist.
• This acquisition expands XOMA's portfolio to over 100 assets, including both commercial and pre-clinical programs.
• The acquired rights include licensing revenue, sublicensing income, milestone payments, and royalty payments.
• The transaction is aimed at enhancing XOMA's risk-adjusted returns for shareholders.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the expansion of XOMA's portfolio and potential for future revenue, but also acknowledges the inherent risks associated with early-stage programs.

Positives

• The acquisition diversifies XOMA's portfolio with over 60 new early-stage programs.
• The deal provides access to potential future revenue streams from milestones and royalties.
• The transaction is expected to enhance XOMA's risk-adjusted returns.
• The upfront payment of $15 million provides Twist with non-dilutive funding.
• XOMA's portfolio now includes over 100 assets, indicating significant growth.

Negatives

• The acquired programs are early-stage, meaning there is no guarantee of commercial success.
• The timing and amount of future milestone and commercial payments are uncertain.
• The success of the acquired assets depends on the progress of Twist's partners.
• There is a risk that the therapeutic product candidates may not receive regulatory approval.

Risks

• The acquired assets are early-stage and may not achieve commercial success.
• The timing and amount of future payments are uncertain and depend on the progress of Twist's partners.
• Regulatory approval for the therapeutic product candidates is not guaranteed.
• The licensees may require substantial funds to continue development, which may not be available.
• There is a risk that a viable market may not exist for the products in which XOMA has an interest.

Future Outlook

The company anticipates potential future milestone and commercial payments from the acquired assets, but these are subject to risks inherent in the biotechnology industry and the progress of Twist's partners.

Management Comments

• Brad Sitko, Chief Investment Officer at XOMA Royalty, stated that the company believes a growing base of commercial revenues coupled with a large and diverse early pipeline have the potential to deliver superior risk-adjusted returns for shareholders.
• The transaction reinforces XOMA's commitment to a disciplined capital deployment strategy and showcases their ability to create bespoke royalty capital solutions.

Industry Context

This transaction highlights the growing trend of royalty monetization in the biotech industry, where companies like XOMA acquire rights to future revenue streams from other companies' drug development programs. This allows biotech companies to raise non-dilutive capital and focus on their core research and development activities.

Comparison to Industry Standards

• XOMA's strategy of acquiring royalty rights is similar to companies like Royalty Pharma, which also focuses on acquiring royalty streams from pharmaceutical and biotech companies.
• The deal with Twist Bioscience is comparable to other royalty monetization deals in the biotech sector, where companies sell a portion of their future revenue streams for upfront capital.
• The focus on early-stage programs is a higher-risk, higher-reward strategy compared to acquiring royalties on commercialized products, which is a common approach for some royalty aggregators.

Stakeholder Impact

• Shareholders may benefit from the potential for increased revenue and returns.
• Twist Bioscience receives non-dilutive funding to advance their programs.
• The transaction may indirectly benefit patients if the acquired programs lead to successful therapies.

Next Steps

• XOMA will monitor the progress of the 60+ early-stage programs acquired from Twist Bioscience.
• XOMA will continue to seek opportunities to expand its royalty and milestone portfolio.

Key Dates

Keywords

royalty, milestone, biopharma, licensing, biotechnology, acquisition, portfolio, therapeutics, XOMA, Twist Bioscience